Clinical Trials Logo

Filter by:
NCT ID: NCT06058611 Recruiting - Clinical trials for Mild Cognitive Impairment

Effects of a Computerised Cognitive Stimulation Versus Stimulating Leisure Activities

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate, at the level of global cognition, cognitive neuroconstructs, memory, verbal fluency, ADLs, IADLs, symptoms of depression and anxiety, the effectiveness of a personalised and adapted computerised cognitive stimulation programme (GI1) implemented from Primary Care versus stimulating leisure activities (GI2), in older adults aged 50 years and over with mild cognitive impairment and subjective cognitive impairment living in the community.

NCT ID: NCT06061913 Recruiting - Clinical trials for Insufficient Breast Milk Syndrome

Comparison of Breast Pump Suction Patterns

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Compare effectiveness of breast pump patterns on lactation outcomes of pump dependent mothers of critically ill infants

NCT ID: NCT06067399 Recruiting - Type 2 Diabetes Clinical Trials

Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

Start date: April 1, 2024
Phase:
Study type: Observational

Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.

NCT ID: NCT06069375 Recruiting - Clinical trials for Medium-chain Acyl-CoA Dehydrogenase Deficiency

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This is a medical research study to test a medication in patients 10 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of sodium phenylbutyrate in patients with MCADD.

NCT ID: NCT06071767 Recruiting - HIV-1-infection Clinical Trials

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus (ChAdV)- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the Toll-like Receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

NCT ID: NCT06077123 Recruiting - Cancer Clinical Trials

Telemonitoring Platforms and Chemotherapy-Associated Toxicity

DETECT
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The primary objective of this trial is to evaluate the impact of a telemonitoring platform on patient satisfaction with care amongst adult cancer patients receiving chemotherapy. The key questions it seeks to address revolve around the potential improvements in both quality of life and satisfaction with healthcare. Participants in the trial will be provided with a specialized application developed by a team of experienced oncology professionals. Their quality of life and healthcare experience will be compared with that of the control group, who will only receive the standard in-person check-ups established by their healthcare team.

NCT ID: NCT06086990 Recruiting - Cancer Clinical Trials

Effects of Telemonitoring in Quality of Life Amongst Cancer Patients

EQUALITE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This interventional study aims to explore the potential of a smartphone app, Contigo, in enhancing the quality of life for patients with various cancers compared to standard care. The investigators will asses effects on quality of life, depressive symptoms, and appointment adherence.

NCT ID: NCT06087757 Recruiting - Williams Syndrome Clinical Trials

Clemastine Treatment in Individuals With Williams Syndrome

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.

NCT ID: NCT06089980 Recruiting - Clinical trials for Kratom Pharmacokinetics

Direct Observation Study of Kratom Product Effects Among Regular Consumers

Start date: April 1, 2024
Phase:
Study type: Observational

The goal of this observational clinical study is to is to learn more about how commercial kratom products affect healthy adults who consume them regularly. The main questions it aims to answer are: 1. What are the acute physiological, subjective, and cognitive effects of kratom following participant self-administration of a single oral dose of the participants usual kratom product at the participants typical dose? 2. What are the physiological, subjective, and cognitive effects associated with kratom product discontinuation among adults who use regularly? 3. What are the pharmacokinetics of kratom products consumed by adults who use regularly? On the first study day: Under direct observation, participants will self-administer a single oral dose of the participants own commercial kratom product that that is regularly taken and will consume it at the participants self-selected typical dose/serving. Following this, serial blood draws and urine collection will occur along with administration of validated questionnaires, tests, and continual monitoring. After this first study day, participants will no longer be permitted to use any of the participants kratom product during the study. On study nights/days 2-3: participants will reside a clinical research unit and be observed and evaluated for kratom withdrawal syndrome.

NCT ID: NCT06097221 Recruiting - Depression Clinical Trials

The Advance Project - Advancing Sleep Timing to Improve Depression

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

150 patients with moderate to severe depression, recently discharged from a psychiatric ward and now recieving treatment at an outpatient unit at Mental Health Center Copenhagen, will be randomised in to two groups. A treatment ad usual (TAU) group and an Advance-group. The Advance-group will receive a psychotherapeutic intervention focusing on advancing sleep timing to improve depression.